During the past decade, Atlanta Diabetes Associates conducted 74 clinical trials. In the 10-year time frame, 74 clinical trials started and 49 clinical trials were completed, i.e. on average, 66.2% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 25 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Atlanta Diabetes Associates" #1 sponsor was "Medtronic Diabetes" with 20 trials, followed by "Eli Lilly and Company" with 8 trials sponsored, "Insulet Corporation" with 6 trials sponsored, "Allergan" with 5 trials sponsored and "DexCom, Inc." with 5 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Atlanta Diabetes Associates" #1 collaborator was "Eli Lilly and Company" with 7 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 4 trials as a collaborator, "Integrated Medical Development" with 3 trials as a collaborator, "Medtronic" with 3 trials as a collaborator and "Atlanta Diabetes Associates" with 2 trials as a collaborator. Other collaborators include 37 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Atlanta Diabetes Associates" are "Type 1 Diabetes Mellitus" (24 trials), "Type 1 Diabetes" (20 trials), "Diabetes Mellitus, Type 1" (16 trials), "Diabetes Mellitus" (12 trials) and "Diabetes Mellitus, Type 2" (11 trials). Many other conditions were trialed in "Atlanta Diabetes Associates" in a lesser frequency.

Most popular intervention types in "Atlanta Diabetes Associates" are "Device" (53 trials), "Drug" (50 trials), "Biological" (6 trials), "Other" (6 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "LY900014" (5 trials), "Omnipod Horizon™ Automated Glucose Control System" (4 trials), "Insulin Degludec" (3 trials) and "Insulin Glargine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Atlanta Diabetes Associates" are 109 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Atlanta Diabetes Associates". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 70 completed trials in Atlanta Diabetes Associates, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Atlanta Diabetes Associates, 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 45 trials that are defined as “Not Applicable".